Pfizer and Sangamo Announce Updated Phase 1/2 Results ...

Pfizer and Sangamo announce updated Phase 1/2 results showing sustained bleeding control in highest dose cohort through two years following hemophilia A gene ...

First patient was dosed in pivotal Phase 3 AFFINE study in October 2020 Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: ...

Pfizer and Sangamo Announce Updated Phase 1/2 Results ...

All five patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2%.

Sangamo and Pfizer Announce Updated Phase 1/2 Results ...

The Phase 1/2 Alta study is an open-label, dose-ranging, multicenter clinical trial designed to assess the safety and tolerability of SB-525 in ...

Sangamo and Pfizer Announce Updated Phase 1/2 Results for SB ...

The data showed that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) activity levels.

Pfizer and Sangamo Announce Updated Phase 1/2 Results ...

Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg ...

Sangamo and Pfizer Announce Phase 1/2 Interim Data for ...

Eight patients total were dosed. Based on these results, the Safety Monitoring Committee (SMC) recommended cohort expansion at the 3e13 vg/kg ...

Pfizer and Sangamo Announce Updated Results in Hemophilia A ...

Pfizer Inc. and Sangamo Therapeutics Inc., a genomic medicines company, announced updated follow-up data from the Phase 1/2 Alta study of ...

Pfizer and Sangamo Dose First Participant in Phase 3 Study ...

Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first ...

Sangamo Therapeutics And Pfizer Announce That SB-525 ...

The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive ...

News Releases | Investor Relations | Sangamo Therapeutics, Inc.

Investors & Media · Sangamo Announces R&D Organization Changes · Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity ...

Sangamo Therapeutics Reports Recent Business Highlights and ...

Reported Pfizer's announcement of positive topline results from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational ...

Press Release Archive - Pfizer

December 2020 · Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x10¹³ VG/KG Cohort Through One Year ...

Sangamo Therapeutics Reports on Pfizer's Announcement of ...

Yahoo Finance · Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy ...

Sangamo Announces Early Completion of Transfer to Pfizer of SB ...

(Nasdaq: SGMO) announced today the completion of the transfer to Pfizer of the SB-525 Hemophilia A gene therapy Investigational New Drug ...

Sangamo Therapeutics Announces Strategic Update and Reports ...

Dosed a total of 25 patients in Phase 1/2 STAAR study in Fabry disease, with promising clinical data continuing to emerge. Deferring additional ...

Pfizer Announces Positive Topline Results From Phase 3 Study of ...

In late 2019, Sangamo transferred the manufacturing technology and the Investigational New Drug application to Pfizer. Under the agreement ...

Sangamo and Pfizer Announce Updated Results of Investigational ...

Sangamo Therapeutics Inc., a genomic medicine company, and Pfizer Inc. announced updated results from the Phase 1/2 Alta study evaluating investigational ...

Gene Therapy for Hemophilia: Progress and Setbacks

Pfizer press release. Pfizer and Sangamo announce updated phase 1/2 results showing sustained factor VIII activity levels and no bleeding ...

Adeno-associated Virus Gene Therapy for Hemophilia - PMC - NCBI

Pfizer. 2021. Pfizer and Sangamo announce updated phase 1/2 results showing sustained bleeding control in highest dose cohort through two ...